PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation

Affiliations

• ¹ Division of Cardiology (A.C., D.M.B., W.C.M., K.A., J.-E.S., J.L., J.M.), Vanderbilt University Medical Center, Nashville, TN.
• ² Cardio-Oncology Program (A.C., W.C.M., K.A., J.-E.S., J.M.), Vanderbilt University Medical Center, Nashville, TN.
• ³ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD (S.B., Q.Z., R.A.A.).
• ⁴ Department of Pathology (J.B.A.), Vanderbilt University Medical Center, Nashville, TN.
• ⁵ Department of Biostatistics (S.H.), Vanderbilt University Medical Center, Nashville, TN.
• ⁶ Department of Pharmacology, Sorbonne University, National Institute of Health and Medical Research, CIC-1901, Public Hospitals of Paris, UNICO-GRECO, Paris, France (L.S.N., J.-E.S.).
• ⁷ Department of Pharmacology, Sorbonne Cardio-Oncology Program, Pitié-Salpêtrière Hospital, Paris, France (L.S.N., J.-E.S.).
• ⁸ Recherche et Innovation, Centres Médico Chirurgicaux Ambroise Paré, Neuilly-sur-Seine, France (L.S.N.).
• ⁹ De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy (E.A.).